Rigel Pharmaceuticals (RIGL) PT Raised to $11 at Piper Jaffray
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and raised his price target to $11.00 (from $10.00) following data this morning.
Shares of Rigel Pharmaceuticals closed at $2.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
- Apple (AAPL) PT Raised to $135 at Brean Capital
- New Oriental Education (EDU) PT Raised to $60 at Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA, Momentum Movers, Trader Talk
Related EntitiesPiper Jaffray, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!